Silvestri Michela, Marando Francesca, Costanzo Anna Maria, di Luzio Paparatti Umberto, Rossi Giovanni A
Pediatric Pulmonology and Allergy Unit and Cystic Fibrosis Center, Istituto Giannina Gaslini, Genoa, Italy.
AbbVie, Medical Department, Campoverde di Aprilia (LT), Campoverde di Aprilia (Latina), Italy.
Ital J Pediatr. 2016 Apr 26;42:40. doi: 10.1186/s13052-016-0252-9.
Due to different social and epidemiological factors, the eligibility criteria to receive palivizumab prophylaxis may be different between countries, especially in "otherwise healthy" late preterm infants.
We analyzed an Italian database of young children referred to emergency departments for acute lower respiratory tract infection (ALRI) during the RSV season over a four year period, when the use of palivizumab as prophylaxis for RSV disease was not widespread in premature infants. The demographic and environmental characteristics and the RSV positivity (RSV(+)) in hospitalized and not-hospitalized patients were compared. In the data analysis we divided children according to their chronologic age (age) and their week gestational age (wGA).
Out of the 100 children evaluated, 68 were infants (≤12 month-age): 7.5 and 20.6 % were in the <29 and 29- < 32 wGA groups respectively, and 72.0 % in the 32- < 35 wGA group. Positive hospitalized-to-not-hospitalized ratios were found in all three wGA groups, progressively decreasing (from 4.0 to 1.2), with increasing wGA (p = 0.35). The percentage of hospitalized infants that were also RSV(+) was also progressively decreasing (from 40.0 to 28.6 % and 18.4 %) with increasing wGA (p = 0.43). In the >12 month-age group (N = 32), there was positive hospitalized-to-not-hospitalized ratio only in the <29 wGA group with a low RSV(+) frequency (<29 %) in all wGA groups. In the ≤12 month-age group, 41 infants were evaluated with a ≤6 month-age and 27 with a >6-12 month-age. A positive hospitalized-to-not-hospitalized ratios was found in all wGA groups in ≤6 month-age infants, despite a low RSV(+) frequency in the 29- < 32 and 32- < 35 wGA group. In the >6-12 month-age group, all infants with a <29 and 29- < 32 wGA were hospitalized with a relatively high RSV(+) frequency whilst the 32- < 35 wGA group showed a negative hospitalized-to-not-hospitalized ratio with a lower RSV(+) frequency.
The hospitalized-to-not-hospitalized ratios and RSV(+) frequency in the first 12 months of age in infants born prematurely confirm the vulnerability of these children for clinically important RSV infection, most notably in the <32 wGA category.
由于不同的社会和流行病学因素,各国接受帕利珠单抗预防的 eligibility 标准可能不同,尤其是在“其他方面健康”的晚期早产儿中。
我们分析了一个意大利儿童数据库,这些儿童在四年的呼吸道合胞病毒(RSV)季节因急性下呼吸道感染(ALRI)被转诊至急诊科,当时帕利珠单抗作为 RSV 疾病预防药物在早产儿中尚未广泛使用。比较了住院和未住院患者的人口统计学和环境特征以及 RSV 阳性(RSV(+))情况。在数据分析中,我们根据儿童的实际年龄(年龄)和孕周(wGA)对其进行了划分。
在评估的 100 名儿童中,68 名是婴儿(≤12 月龄):分别有 7.5%和 20.6%在<29 和 29 - <32 wGA 组,72.0%在 32 - <35 wGA 组。在所有三个 wGA 组中均发现住院与未住院的阳性比率,随着 wGA 的增加逐渐降低(从 4.0 降至 1.2)(p = 0.35)。随着 wGA 的增加,住院婴儿中 RSV(+)的百分比也逐渐降低(从 40.0%降至 28.6%和 18.4%)(p = 0.43)。在>12 月龄组(N = 32)中,仅在<29 wGA 组存在住院与未住院的阳性比率,所有 wGA 组中 RSV(+)频率均较低(<29%)。在≤12 月龄组中,评估了 41 名≤6 月龄的婴儿和 27 名>6 - 12 月龄的婴儿。在≤6 月龄婴儿的所有 wGA 组中均发现住院与未住院的阳性比率,尽管在 29 - <32 和 32 - <35 wGA 组中 RSV(+)频率较低。在>6 - 12 月龄组中,所有<29 和 29 - <32 wGA 的婴儿均住院,RSV(+)频率相对较高,而 32 - <35 wGA 组的住院与未住院比率为阴性,RSV(+)频率较低。
早产儿出生后前 12 个月的住院与未住院比率以及 RSV(+)频率证实了这些儿童易患具有临床重要性的 RSV 感染,最明显的是在<32 wGA 类别中。